Print ArticleAgilent Technologies Inc. (NYSE: A) introduced a high-capacity version of its human protein Multiple Affinity Removal System, which removes up to 99 percent of the six most common proteins from human blood serum. The new system allows researchers to purify approximately twice the volume of serum per sample compared with other protein removal systems, and will facilitate the detection and identification of low-abundance proteins that may serve as markers for a wide range of diseases.
Proteins that are representative of disease processes are typically present in small amounts in human serum and may be difficult to isolate amid high-abundance proteins such as albumin. By doubling the throughput of protein removal, the new Agilent High-Capacity Multiple Affinity Removal System makes it easier for researchers to eliminate high-abundance proteins from larger sample volumes.
"This high-capacity system will help to improve the speed, efficiency and productivity of human biomarker research," said Mary Pat Knauss, bioreagents business manager at Agilent. "Along with our ongoing efforts to develop methods for removing an even greater number of high-abundance proteins from serum or plasma, the new system promises to enhance scientists' ability to delve into the human proteome and advance the progress of proteomic research."
The new high-capacity affinity removal system is available in both HPLC column and spin cartridge formats, facilitating protein removal through liquid chromatography (LC) or centrifugation techniques. The new high-capacity products can be reused for more than 200 runs and are compatible with most standard LC instruments and benchtop centrifuges.
The High-Capacity Multiple Affinity Removal System is available now. Additional information is available at www.agilent.com/chem/MARS.
Source : Agilent
Mail to a Friend
Link to this article
